Comparison of the <i>in vivo</i> efficacy and resistance development potential between cefiderocol and ceftolozane/tazobactam human simulated exposures against <i>Pseudomonas aeruginosa in</i> 72-hour murine thigh infection model-Reference-Cited by-同舟云学术

Comparison of the in vivo efficacy and resistance development potential between cefiderocol and ceftolozane/tazobactam human simulated exposures against Pseudomonas aeruginosa in 72-hour murine thigh infection model

Published:2025-03-05 Issue:7 Volume:57 Page:658-668
ISSN:2374-4235
Container-title:Infectious Diseases
language:en
Short-container-title:Infectious Diseases

Author:

Fouad Aliaa¹,Nicolau Samantha E.²,Tamma Pranita D.³,Simner Patricia J.⁴,Nicolau David P.¹⁵,Gill Christian M.¹

Affiliation:

1. Center for Anti-Infective Research and Development, Hartford Hospital

2. mRNA Center of Excellence, Sanofi Pasteur

3. Department of Pediatrics, Johns Hopkins University School of Medicine

4. Department of Pathology, Johns Hopkins University School of Medicine

5. Division of Infectious Diseases, Hartford Hospital

Funder

Shionogi & Co., Ltd., Japan

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/23744235.2025.2471822

Reference53 articles.

1. Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections

2. The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa

3. CDC. Antibiotic resistance threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019.

4. Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network, 2015–2017

5. Carbapenemase-Producing Organisms: A Global Scourge